Immunohistochemistry (IHC) Market Size, Share, Growth, and Industry Analysis, By Type (Antibodies, Equipment, Reagents), By Application (Diagnostics, Research), Regional Insights and Forecast to 2035

Immunohistochemistry (IHC) Market Overview

The global Immunohistochemistry (IHC) Market size estimated at USD 2953.25 million in 2026 and is projected to reach USD 5901.45 million by 2035, growing at a CAGR of 8% from 2026 to 2035.

The Immunohistochemistry (IHC) Market is a critical segment of the global pathology and diagnostics industry, driven by increasing utilization of tissue-based biomarker analysis in oncology, infectious disease diagnosis, and personalized medicine. Immunohistochemistry techniques are widely used for detecting protein expression in tissue samples, supporting accurate disease classification and treatment selection. The diagnostics application segment accounts for more than 68% of overall market demand, while antibodies represent over 41% of product utilization. North America contributes nearly 38% of global market activity due to widespread adoption of advanced pathology workflows. Growing volumes of cancer screening, companion diagnostics, and automated staining technologies continue to strengthen Immunohistochemistry (IHC) Market Growth and Immunohistochemistry (IHC) Market Share worldwide.

The United States remains the largest contributor to the Immunohistochemistry (IHC) Market, supported by extensive cancer diagnostic infrastructure and advanced pathology laboratories. More than 1.9 million new cancer cases are diagnosed annually in the country, creating substantial demand for biomarker testing and tissue diagnostics. Hospitals and diagnostic laboratories account for over 70% of IHC utilization, while companion diagnostic applications continue to expand across breast, lung, ovarian, and colorectal cancer testing. Automated staining platforms and digital pathology integration have increased laboratory efficiency by over 30% in many large pathology centers. The presence of major biotechnology companies, strong regulatory support for companion diagnostics, and increasing adoption of precision oncology continue to reinforce the U.S. leadership position in the Immunohistochemistry (IHC) Market Outlook.

Download Free Sample to learn more about this report.

Key Findings

• Market Size & Growth: Diagnostics applications account for more than 68.6% of total demand, antibodies represent 41.4% of product usage, hospitals and diagnostic laboratories contribute over 70.4% of end-user consumption, and North America holds approximately 37.8% of global market activity.
• Key Market Driver: More than 68% of IHC procedures are linked to diagnostic applications, while over 60% of biomarker-based oncology assessments utilize tissue staining technologies. Companion diagnostic testing volumes have increased by over 40%, supporting widespread adoption across pathology laboratories.
• Major Market Restraint: Approximately 22%–28% of laboratories report workflow delays related to manual staining procedures, while nearly 18% of pathology facilities face shortages of specialized personnel. Reagent variability can impact up to 15% of testing consistency across decentralized laboratories.
• Emerging Trends: Automated staining adoption exceeds 55% among large diagnostic centers, while digital pathology integration has expanded by nearly 45%. Multiplex immunohistochemistry implementation has increased by over 35% as precision oncology programs continue expanding globally.
• Regional Leadership: North America contributes approximately 37.8% of global demand, while Asia-Pacific accounts for nearly 25% and Europe represents around 28%. More than 65% of advanced companion diagnostic testing is concentrated within North American and European healthcare systems.
• Competitive Landscape: The top ten industry participants collectively account for more than 60% of technology deployment. Automated instrument penetration exceeds 50% among leading pathology laboratories, while strategic partnerships and product approvals have increased by nearly 30% during recent years.
• Market Segmentation: Antibodies represent 41.4% of product demand, diagnostics exceed 68.6% of applications, and hospitals and diagnostic laboratories contribute over 70.4% of end-user utilization. Research applications account for approximately 31% of total market activity.
• Recent Development: More than 25% growth in companion diagnostic approvals has been observed in recent years. FDA-supported biomarker assays increased by over 20%, while advanced oncology-focused IHC solutions expanded by nearly 30% across precision medicine programs.

Immunohistochemistry (IHC) Market Latest Trends

The Immunohistochemistry (IHC) Market Trends are increasingly shaped by automation, artificial intelligence integration, and precision oncology requirements. Automated staining systems are becoming standard across large pathology laboratories, with adoption levels surpassing 55% among advanced diagnostic centers. Digital pathology platforms capable of image analysis and biomarker quantification have improved workflow productivity by more than 30%. Multiplex immunohistochemistry technologies are gaining significant traction, allowing simultaneous evaluation of multiple biomarkers from a single tissue sample. This trend is particularly important for oncology applications where biomarker profiling directly influences treatment decisions. 

Another significant trend within the Immunohistochemistry (IHC) Market Analysis is the rapid expansion of companion diagnostics. Global pathology laboratories are increasingly utilizing IHC assays for biomarkers such as HER2, PD-L1, ER, PR, and FOLR1 to identify eligible patients for targeted therapies. More than 12 million companion diagnostic-related IHC tests are conducted annually worldwide. Artificial intelligence-assisted interpretation is also emerging as a transformative technology, enabling improved consistency and reduced observer variability. Research institutions are developing advanced AI models trained on datasets containing over 10 million IHC images, supporting automated assessment of staining intensity and tissue characteristics. 

Immunohistochemistry (IHC) Market Dynamics

DRIVER

"Rising Demand for Cancer Diagnostics and Biomarker Testing"

The primary driver supporting Immunohistochemistry (IHC) Market Growth is the increasing prevalence of cancer and the growing reliance on biomarker-based diagnosis. More than 68% of all IHC applications are associated with diagnostics, particularly oncology. IHC remains one of the most widely utilized ancillary tests in histopathology because it enables precise identification of tumor origin, protein expression, and treatment eligibility. The technology plays a critical role in evaluating biomarkers including HER2, PD-L1, ER, PR, and ALK. Increasing adoption of companion diagnostics has resulted in millions of tissue-based biomarker assessments annually. 

RESTRAINTS

"Complex Laboratory Workflows and Skilled Personnel Requirements"

A significant restraint affecting the Immunohistochemistry (IHC) Market is the complexity of laboratory workflows and dependence on trained pathology professionals. Accurate interpretation of tissue staining requires highly specialized expertise, creating operational challenges for healthcare facilities experiencing workforce shortages. Manual staining procedures remain common in many regions and can lead to variability in results, increased turnaround times, and reduced laboratory efficiency. 

OPPORTUNITY

"Expansion of Personalized Medicine and Companion Diagnostics"

The strongest opportunity in the Immunohistochemistry (IHC) Market Forecast is the rapid expansion of personalized medicine programs. Targeted therapies increasingly require biomarker confirmation before treatment initiation, making IHC a critical component of clinical decision-making. Companion diagnostic testing volumes continue to rise as pharmaceutical companies develop precision therapies for oncology and rare diseases. More than 12 million IHC-based companion diagnostic tests are currently performed annually worldwide, demonstrating substantial demand. 

CHALLENGE

"Rising Operational Costs and Standardization Requirements"

One of the key challenges facing the Immunohistochemistry (IHC) Market is the increasing operational burden associated with quality control, regulatory compliance, and laboratory standardization. Modern pathology laboratories must manage large testing volumes while maintaining reproducibility across thousands of tissue samples. Advanced automation systems, digital pathology infrastructure, and AI-assisted platforms require substantial capital investment and ongoing maintenance. 

Immunohistochemistry (IHC) Market Segmentation

The Immunohistochemistry (IHC) Market is segmented by type and application, reflecting structured demand across diagnostic laboratories, hospitals, biotechnology firms, and research institutions. By type, the market includes antibodies, equipment, and reagents, each contributing uniquely to tissue staining workflows. By application, diagnostics dominates due to rising cancer burden, while research expands rapidly with biomarker discovery and drug development activities worldwide.

Download Free Sample to learn more about this report.

BY TYPE

Antibodies: Antibodies are the core functional component of the Immunohistochemistry (IHC) Market, responsible for antigen detection in tissue samples. This segment contributes the highest utilization share, accounting for more than 40% of consumable usage in pathology workflows. Monoclonal antibodies dominate due to their high specificity, consistency, and suitability for automated platforms, while polyclonal antibodies remain relevant for broader antigen detection. More than 80% of oncology-based IHC testing relies on antibody-driven detection systems for identifying biomarkers such as HER2, PD-L1, ER, PR, ALK, and Ki-67. Increasing cancer incidence has significantly expanded antibody consumption across diagnostic laboratories. Millions of tissue samples are processed annually, with antibody panels forming the foundation of tumor classification and treatment selection. Companion diagnostics require validated antibodies to determine patient eligibility for targeted therapies, driving large-scale adoption across healthcare systems. 

Equipment: Equipment in the Immunohistochemistry (IHC) Market includes automated staining systems, tissue processors, slide scanners, imaging platforms, and digital pathology instruments. Automated staining systems dominate this segment, with more than 55% of high-throughput laboratories relying on automation to improve consistency and reduce manual errors. These systems can process hundreds of slides daily, improving productivity by over 30% compared to manual staining methods. Digital pathology adoption is accelerating, with over 45% of advanced diagnostic laboratories integrating whole-slide imaging systems for remote diagnosis and AI-assisted interpretation. These platforms enhance workflow efficiency, reduce turnaround time, and improve diagnostic accuracy. 

Reagents: Reagents form a vital consumable segment in the Immunohistochemistry (IHC) Market, including detection kits, chromogens, buffers, antigen retrieval solutions, blocking agents, and mounting media. These consumables are essential for every staining procedure, making them a continuously recurring demand category across laboratories worldwide. More than 68% of immunohistochemistry procedures are diagnostic in nature, directly driving reagent consumption across oncology and disease classification workflows. Standardized reagent systems are increasingly preferred to minimize variability and improve reproducibility across laboratories. Millions of slides are processed annually using reagent-based staining protocols. Advanced reagent formulations are improving assay sensitivity and reducing background noise, enabling clearer visualization of biomarkers. 

BY APPLICATION

Diagnostics: Diagnostics is the leading application segment in the Immunohistochemistry (IHC) Market, contributing more than 68% of total utilization. It is widely used in oncology for tumor identification, classification, and biomarker-based treatment selection. Immunohistochemistry enables detection of key biomarkers such as HER2, PD-L1, ER, PR, ALK, and EGFR, which guide clinical decisions in breast, lung, colorectal, and prostate cancers. Millions of tissue samples are analyzed annually using IHC-based diagnostic workflows. More than 80% of advanced oncology centers rely on immunohistochemistry for routine cancer diagnosis. Companion diagnostics are a major driver, requiring validated IHC assays before initiation of targeted therapies. This has significantly increased test volumes across hospitals and diagnostic laboratories. 

Research: Research is a rapidly expanding application in the Immunohistochemistry (IHC) Market, accounting for nearly one-third of total usage. It is extensively used in academic institutions, pharmaceutical companies, and biotechnology organizations for biomarker discovery and drug development. Immunohistochemistry enables researchers to study protein expression, disease mechanisms, and cellular interactions within tissue samples. Large-scale research programs analyze hundreds of biomarkers across thousands of specimens to identify disease pathways. Precision medicine initiatives have significantly increased demand for advanced tissue-based research tools. Pharmaceutical companies use IHC in preclinical and clinical studies to evaluate drug efficacy, target engagement, and biological response. 

Immunohistochemistry (IHC) Market Regional Outlook

The Immunohistochemistry (IHC) Market demonstrates a highly structured regional distribution, with North America, Europe, and Asia-Pacific collectively contributing more than 92% of the global demand, while the remaining share is distributed across the Middle East & Africa and Latin America. North America holds approximately 38% share due to advanced diagnostic infrastructure and high cancer testing volumes. Europe accounts for nearly 28% share driven by strong healthcare systems and research funding. Asia-Pacific contributes around 25% share supported by rising healthcare investments and expanding laboratory networks. The remaining 9% is held by emerging regions where adoption is gradually increasing with improvements in diagnostic accessibility and pathology services.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America leads the Immunohistochemistry (IHC) Market with approximately 38% share of global demand, driven by strong diagnostic infrastructure, advanced oncology screening programs, and widespread adoption of companion diagnostics. The region processes millions of immunohistochemistry tests annually, with over 70% of procedures conducted in hospitals and diagnostic laboratories. More than 80% of cancer centers in the United States and Canada rely on IHC for tumor classification and biomarker evaluation. Automated staining systems are used in nearly 60% of high-throughput laboratories, improving workflow efficiency by over 30% compared to manual processes. Digital pathology adoption exceeds 45%, supporting remote diagnosis and AI-assisted interpretation. The increasing incidence of cancer, with more than 1.9 million new cases annually in the United States alone, continues to drive demand for antibody-based testing and reagent consumption. Companion diagnostic testing has expanded significantly, with over 12 million IHC-based biomarker evaluations conducted annually. Precision medicine initiatives and strong regulatory frameworks further support growth. The region’s CAGR performance remains stable due to consistent adoption of advanced technologies and strong research funding exceeding 65% participation from public-private collaborations. 

EUROPE

Europe accounts for nearly 28% share of the Immunohistochemistry (IHC) Market, supported by strong healthcare systems, advanced diagnostic laboratories, and increasing adoption of precision medicine. More than 75% of tertiary hospitals across major European countries utilize immunohistochemistry for cancer diagnosis and disease classification. Oncology testing represents over 65% of total IHC applications in the region, with breast, lung, and colorectal cancers forming the highest diagnostic volumes. Automated staining systems are implemented in approximately 50% of pathology laboratories, improving consistency and reducing diagnostic variability by over 25%. Digital pathology adoption is expanding rapidly, with nearly 40% of laboratories integrating image analysis platforms for remote consultation and research applications. Europe processes millions of tissue samples annually, with biomarker testing forming a critical part of clinical decision-making. Companion diagnostics are widely adopted, especially in Western Europe, where over 70% of oncology centers rely on IHC-based biomarker validation. Research funding contributes significantly to market expansion, with more than 55% of academic institutions engaged in biomarker discovery and translational research.

GERMANY IMMUNOHISTOCHEMISTRY (IHC) Market

Germany holds approximately 7% share of the global Immunohistochemistry (IHC) Market and represents one of the most advanced diagnostic ecosystems in Europe. More than 85% of major hospitals in Germany utilize immunohistochemistry for oncology diagnostics, pathology classification, and biomarker testing. The country processes millions of tissue samples annually, with breast and lung cancer representing over 60% of total IHC diagnostic applications. Automated staining platforms are used in nearly 55% of pathology laboratories, improving workflow efficiency by more than 30%. Digital pathology adoption is steadily increasing, with around 40% of laboratories implementing whole-slide imaging systems for diagnostic accuracy and research applications. Germany’s strong biotechnology sector contributes significantly to antibody development, with more than 45% of research institutions actively engaged in biomarker discovery programs. Companion diagnostics are widely adopted, particularly in oncology centers where over 75% of targeted therapy decisions depend on IHC-based testing. 

UNITED KINGDOM IMMUNOHISTOCHEMISTRY (IHC) Market

The United Kingdom contributes approximately 6% share to the global Immunohistochemistry (IHC) Market, driven by a highly structured public healthcare system and strong cancer screening programs. More than 80% of pathology laboratories in the UK utilize immunohistochemistry for diagnostic and research applications. The National Health Service processes millions of tissue samples annually, with oncology diagnostics representing over 70% of total IHC usage. Breast cancer, lung cancer, and prostate cancer are the primary disease areas driving antibody and reagent consumption. Automated staining systems are implemented in nearly 50% of major diagnostic centers, improving diagnostic turnaround times by more than 25%. Digital pathology adoption is expanding, with approximately 35% of laboratories integrating AI-supported imaging platforms for enhanced diagnostic accuracy. The UK also has a strong academic research base, with over 60% of universities engaged in biomarker discovery and translational medicine projects. 

ASIA-PACIFIC

The Asia-Pacific region holds approximately 25% share of the Immunohistochemistry (IHC) Market and is emerging as the fastest-expanding regional segment due to rising healthcare investments and increasing cancer burden. More than 60% of new diagnostic laboratories in the region are adopting immunohistochemistry technologies to support cancer screening and disease classification. China, Japan, and India collectively account for over 80% of regional demand. Oncology diagnostics represent more than 70% of total IHC usage, driven by increasing incidence of breast, lung, and gastrointestinal cancers. Automated staining systems are used in nearly 45% of advanced laboratories, improving testing efficiency by over 30%. Digital pathology adoption is growing rapidly, with approximately 35% of large hospitals integrating imaging and AI-based diagnostic systems. The region processes millions of tissue samples annually, with significant growth in biomarker-based testing. Government initiatives supporting healthcare modernization contribute to rising adoption rates. Research institutions account for nearly 40% of IHC usage in Asia-Pacific, particularly in biomarker discovery and pharmaceutical development. 

JAPAN IMMUNOHISTOCHEMISTRY (IHC) Market

Japan accounts for approximately 6% share of the global Immunohistochemistry (IHC) Market and is recognized for its advanced diagnostic technologies and high healthcare standards. More than 85% of major hospitals in Japan utilize immunohistochemistry for oncology and pathology diagnostics. Cancer screening programs are highly developed, with millions of tissue samples processed annually. Breast, gastric, and lung cancers represent over 65% of total IHC applications in the country. Automated staining systems are used in nearly 60% of pathology laboratories, improving diagnostic consistency and reducing manual variability by more than 30%. Digital pathology adoption exceeds 40%, with increasing use of AI-assisted image analysis in large hospital networks. Japan’s strong pharmaceutical sector contributes significantly to biomarker research, with more than 50% of biotechnology firms engaged in antibody development and companion diagnostic innovation. Precision medicine initiatives are widely implemented, with over 70% of oncology treatment decisions supported by IHC-based testing. Continuous technological innovation and strong healthcare infrastructure ensure Japan’s stable position in the Immunohistochemistry (IHC) Market Outlook.

CHINA IMMUNOHISTOCHEMISTRY (IHC) Market

China holds approximately 12% share of the global Immunohistochemistry (IHC) Market and represents one of the fastest-growing diagnostic markets worldwide. More than 70% of major hospitals in China utilize immunohistochemistry for cancer diagnosis and disease classification. The country processes millions of tissue samples annually, with oncology representing over 75% of total IHC applications. Automated staining systems are used in approximately 40% of advanced laboratories, improving workflow efficiency by over 30%. Digital pathology adoption is rapidly increasing, with nearly 35% of tertiary hospitals implementing AI-based diagnostic platforms. China’s large patient population, with millions of new cancer cases annually, drives strong demand for antibody-based testing and reagent consumption. Government healthcare reforms and investments in diagnostic infrastructure are supporting rapid expansion of laboratory networks. Research institutions account for more than 45% of IHC usage, particularly in biomarker discovery and pharmaceutical development. Increasing collaboration between domestic and global biotechnology companies continues to enhance innovation capacity, strengthening China’s position in the Immunohistochemistry (IHC) Market Growth trajectory.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 9% share of the Immunohistochemistry (IHC) Market and is gradually expanding due to improving healthcare infrastructure and rising cancer awareness. More than 55% of tertiary hospitals in urban areas have adopted immunohistochemistry for diagnostic purposes, particularly in oncology. Breast and colorectal cancers represent over 60% of total IHC applications in the region. Automated staining systems are used in nearly 30% of advanced laboratories, improving diagnostic efficiency by over 20%. Digital pathology adoption remains limited but is gradually increasing, with around 20% of major healthcare centers implementing imaging systems. The region processes millions of diagnostic tissue samples annually, with growing reliance on biomarker testing for disease classification. Government healthcare investments are improving access to diagnostic technologies, particularly in Gulf Cooperation Council countries, where adoption rates exceed 50% in major hospitals. Research activity contributes nearly 35% of regional IHC usage, primarily in academic and clinical research institutions. Increasing awareness of precision medicine and expanding oncology care infrastructure continue to support steady growth in the Immunohistochemistry (IHC) Market Outlook across emerging economies.

List of Key Immunohistochemistry (IHC) Market Companies

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam plc

Top Two Companies with Highest Share

• Thermo Fisher Scientific Inc.: Holds approximately 18%–20% share due to strong antibody portfolio, automated staining systems, and global diagnostic laboratory penetration exceeding 60% in major hospital networks.
• F. Hoffmann-La Roche Ltd.: Accounts for nearly 15%–17% share supported by dominance in companion diagnostics, oncology biomarker testing, and presence in more than 70% of advanced cancer testing workflows.

Investment Analysis and Opportunities

The Immunohistochemistry (IHC) Market presents strong investment potential driven by increasing diagnostic adoption and biomarker-based oncology testing. More than 68% of global demand is concentrated in diagnostic applications, creating sustained investment opportunities in antibody production, automated staining systems, and reagent manufacturing. Around 55% of laboratories are transitioning toward automation, indicating significant capital deployment potential in workflow modernization technologies. Digital pathology adoption exceeding 45% in developed regions highlights opportunities in AI-based imaging platforms and cloud-integrated diagnostic systems. Investors are increasingly targeting companies involved in multiplex immunohistochemistry, which is growing in adoption by more than 35% across research and clinical settings. Rising cancer incidence, with millions of new cases annually worldwide, further strengthens demand for advanced diagnostic infrastructure.

Strategic opportunities are also emerging in emerging markets where only 30%–40% of laboratories have fully adopted advanced immunohistochemistry systems. Expansion in Asia-Pacific and Middle East regions is expected to drive infrastructure investments, particularly in oncology-focused diagnostic centers. Approximately 40% of research funding is now directed toward biomarker discovery and precision medicine, supporting long-term innovation pipelines. Partnerships between biotechnology firms and diagnostic companies account for over 50% of recent technology developments, indicating strong collaborative investment potential. Growing emphasis on companion diagnostics, representing more than 12 million annual tests globally, further enhances market scalability and returns.

New Products Development

New product development in the Immunohistochemistry (IHC) Market is focused on improving diagnostic accuracy, automation, and multiplex capabilities. More than 60% of newly introduced products are centered on automated staining systems and advanced antibody panels designed for high specificity. Companies are increasingly developing recombinant antibodies, which reduce variability by over 30% compared to traditional formulations. Multiplex IHC platforms are gaining strong traction, enabling simultaneous detection of multiple biomarkers within a single tissue sample, improving analytical efficiency by nearly 40%.

Innovation in reagent chemistry is also advancing, with over 50% of new product launches focusing on enhanced detection sensitivity and reduced background staining. Digital pathology integration is a key focus area, with approximately 45% of new systems offering AI-based image analysis capabilities. Manufacturers are also developing ready-to-use reagent kits, reducing laboratory preparation time by over 20%. Increasing demand for precision oncology and companion diagnostics continues to drive innovation, with more than 35% of new products designed specifically for biomarker-driven clinical applications.

Five Recent Developments

• Thermo Fisher Scientific Inc.: Expanded its automated staining portfolio adoption by over 20% across hospital laboratories, improving diagnostic throughput and workflow efficiency in oncology testing environments.
• Roche Diagnostics: Increased integration of companion diagnostic platforms by nearly 25% in oncology centers, strengthening biomarker-based treatment selection capabilities across global healthcare networks.
• Agilent Technologies, Inc.: Introduced enhanced antibody panels improving staining sensitivity by approximately 30%, supporting more accurate tumor classification in pathology workflows.
• Danaher Corporation: Reported expansion of digital pathology systems adoption by over 35% in large diagnostic laboratories, enabling AI-assisted image analysis and remote consultation capabilities.
• Bio-Rad Laboratories, Inc.: Advanced multiplex immunohistochemistry solutions with nearly 40% improvement in biomarker detection efficiency, supporting research and clinical oncology applications.

Report Coverage Of Immunohistochemistry (IHC) Market

The Immunohistochemistry (IHC) Market report coverage includes comprehensive analysis of market structure, segmentation, regional distribution, and competitive landscape, accounting for 100% of global market activity across diagnostics and research applications. The study evaluates more than 90% of laboratory adoption patterns across hospitals, diagnostic centers, and research institutions worldwide. Approximately 68% of the market is driven by diagnostic applications, while research contributes nearly 32%, highlighting balanced demand distribution.The report further covers technological penetration, where automated staining systems account for over 55% adoption in high-throughput laboratories and digital pathology systems represent nearly 45% of advanced diagnostic setups. Regional analysis includes North America with around 38% share, Europe with 28%, Asia-Pacific with 25%, and remaining regions collectively contributing 9%.

Competitive benchmarking evaluates leading companies controlling more than 70% of the market influence through product innovation and strategic partnerships. Additional insights include segmentation by antibodies, equipment, and reagents, which collectively represent 100% of product demand structure. The report also highlights more than 60% growth influence from oncology applications and companion diagnostics. Investment analysis shows over 50% of capital flow directed toward automation, AI integration, and biomarker-based testing solutions, reinforcing strong long-term Immunohistochemistry (IHC) Market Outlook and strategic expansion opportunities.